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ABSTRACT
Anti-cancer agents exert therapeutic effects by damaging DNA. Unfortunately, 
DNA polymerases can effectively replicate the formed DNA lesions to cause drug 
resistance and create more aggressive cancers. To understand this process at the 
cellular level, we developed an artificial nucleoside that visualizes the replication of 
damaged DNA to identify cells that acquire drug resistance through this mechanism. 
Visualization is achieved using "click" chemistry to covalently attach azide-containing 
fluorophores to the ethynyl group present on the nucleoside analog after its 
incorporation opposite damaged DNA. Flow cytometry and microscopy techniques 
demonstrate that the extent of nucleotide incorporation into genomic DNA is enhanced 
by treatment with DNA damaging agents. In addition, this nucleoside analog inhibits 
translesion DNA synthesis and synergizes the therapeutic activity of certain anti-
cancer agents such as temozolomide. The combined diagnostic and therapeutic 
activities of this synthetic nucleoside analog represent a new paradigm in personalized 
medicine.
INTRODUCTION
Cellular DNA is constantly exposed to a wide 
variety of internal and external DNA damaging agents. 
While cells possess several pathways to correct damaged 
DNA, some lesions unfortunately escape repair and 
their presence can produce devastating cellular effects 
ranging from mutagenesis and genomic rearrangements 
to cell death. One conserved mechanism to tolerate 
unrepaired DNA lesions involves their efficient by-pass 
in a process termed translesion DNA synthesis (TLS). 
Since most high-fidelity DNA polymerases involved in 
chromosomal replication cannot efficiently replicate and 
bypass damaged DNA, cells rely heavily on the activity 
of specialized DNA polymerases to accomplish this task 
[1]. A complete understanding of how these polymerases 
function at the cellular level has been hindered by 
the diversity of DNA lesions that form inside a cell 
coupled with the large number of DNA polymerases that 
participate in their replication. In humans, for example, 
at least seven of the 15 different DNA polymerases can 
replicate structurally diverse DNA lesions such as thymine 
dimers, abasic sites, and double strand DNA breaks [2–6]. 
Understanding how TLS activity is regulated at 
the cellular level is especially relevant in cancer patients 
receiving chemotherapy [7–11]. For example, a significant 
complication of TLS is the onset of drug resistance 
caused by misreplicating the DNA lesions produced by 
agents such as temozolomide (TMZ) and cisplatin [7–9] 
(Figure 1A). Furthermore, the pro-mutagenic outcomes 
of TLS can increase the frequency of genetic mutations 
and create more aggressive cancers. Indeed, Johnson et al. 
recently reported that brain tumors isolated from patients 
treated with TMZ became drug resistant as a result of 
acquired somatic mutations in genes associated with DNA 
mismatch repair [10]. These tumors were hypermutated 
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and contained more than 30 mutations per megabase 
whereas initial untreated tumors had significantly lower 
mutation frequencies (0.2 to 4.5 mutations per Mb) [10]. 
Despite the importance of TLS, there are no 
chemical compounds that can monitor this process at 
the cellular level. We have addressed this problem by 
developing nucleotide analogs that are efficiently and 
selectively incorporated opposite DNA lesions generated 
by DNA damaging agents. One therapeutically important 
DNA lesion is the abasic site which is non-enzymatically 
formed by DNA alkylating agents such as TMZ and 
enzymatically by DNA glycosylases [12]. We developed an 
artificial nucleotide designated 3-ethynyl-5-nitroindolyl-
2’-deoxyriboside triphosphate (3-Eth-5-NITP) (Figure 
1B) that functions as an efficient surrogate for the natural 
nucleotide, dATP, that is preferentially utilized during TLS 
[13]. In this report, we use the corresponding nucleoside, 
3-Eth-5-NIdR, to track TLS activity in cancer cells treated 
with compounds that generate abasic sites. Visualizing the 
replication of these lesions was achieved using copper-
catalyzed “click” chemistry to tag the ethynyl moiety 
present on the nucleotide with fluorogenic probes. This 
represents a new diagnostic technique to quantify drug 
resistance caused by TLS activity. In addition, co-treating 
leukemia cells with 3-Eth-5-NIdR and anti-cancer agents 
that generate abasic sites causes a synergistic increase 
in cell death and correlates with the amount of 3-Eth-5-
NITP incorporated into genomic DNA. Collectively, the 
diagnostic and therapeutic activities of this novel artificial 
nucleoside provide a new paradigm in personalized 
medicine for cancer treatment.  
RESULTS
Measuring the cellular replication of abasic sites
In order to study the cellular replication of damaged 
DNA, it was necessary to generate abasic sites inside cells. 
This was achieved by using the enzymatic activity of 
uracil DNA glycosylase to produce abasic sites by excising 
uracil from DNA (Figure 2A). In these experiments, 
MOLT4 leukemia cells were treated with 5 μM uracil 
2-deoxyribose (UdR) or DMSO (vehicle control). After 
72 hours post-treatment, genomic DNA was isolated and 
the number of abasic sites in DNA was quantified using 
the aldehyde reactive probe (ARP) assay [14]. Figure 2B 
shows that cells treated with 5 µM UdR have a ~4-fold 
higher number of abasic sites compared to cells treated 
with DMSO. 
The viability of MOLT4 cells treated with 5 µM UdR 
was also measured using two independent biochemical 
assays (visualization by microscopy and flow cytometry). 
Figure 2C shows that cells treated with 5 µM UdR have 
a ~3-fold higher level of cell death compared to DMSO 
treatment. Cells treated with 10 µg/mL 3-Eth-5-NIdR 
(which corresponds to a molar concentration of 33 µM) 
show a 2-fold increase in cell death. More importantly, 
cells treated with a low concentration of 3-Eth-5-NIdR (10 
µg/mL) and 5 µM UdR show a synergistic increase in cell 
death that is 2.5-fold higher than the additive effects of 
UdR and 3-Eth-5-NIdR treatment (Figure 2C). The ability 
of 3-Eth-5-NIdR to increase the cell killing effects of UdR 
likely reflects the ability of the corresponding nucleoside 
triphosphate, 3-Eth-5-NITP, to effectively block the 
replication of unrepaired abasic sites. 
We verified that this synergistic effect is caused 
by inhibiting TLS activity using dual parameter flow 
cytometry (propidium iodide (PI) and fluorescence 
detection of the artificial nucleotide) to measure the 
amount of AlexaFluor488 covalently attached to 3-Eth-5-
NIdR incorporated into genomic DNA. Figure 2D shows 
that MOLT4 cells treated with DMSO or 5 µM UdR have 
low levels (< 0.5%) of AlexaFluor488 labeled DNA. Cells 
treated with 10 µg/mL 3-Eth-5-NIdR for two days display 
low but appreciable levels of AlexaFluor488 labeled DNA 
(1.1%). This low level is consistent with previous results 
demonstrating that 3-Eth-5-NIdR can detect the cellular 
activity of terminal deoxynucleotidyl transferase (TdT) 
which is overexpressed in MOLT4 cells [15]. However, 
cells co-treated with 10 µg/mL Eth-5-NIdR and 5 µM UdR 
show more robust effects as there is a ~6-fold increase 
in AlexaFluor488 labeled DNA (6.4%). The increase 
in “clicked” DNA likely occurs by the incorporation of 
3-Eth-5-NITP opposite abasic sites formed after uracil 
excision. The amount of 3-Eth-5-NIdR utilized during TLS 
was compared to the amount of 5-ethynyl-2’deoxyribose 
uracil (EdU) incorporated during normal DNA synthesis 
(Figure 2D). As expected, cells treated with 10 µM EdU 
have considerably higher levels “clicked” genomic DNA 
(35.2%) compared to cells treated with UdR and 3-Eth-5-
NIdR (6.4%). In general, the higher amount of "clicked" 
DNA with EdU treatment results from the efficient 
insertion of the thymine analog opposite adenine which 
occurs with a significantly higher frequency in genomic 
DNA compared to unrepaired abasic sites. 
Specialized DNA polymerases preferentially 
insert 3-Eth-5-NITP opposite abasic sites
We next investigated which cellular DNA polymerases 
may be responsible for incorporating 3-Eth-5-NITP opposite 
abasic sites formed after UdR treatment. In vitro approaches 
measured the kinetic parameters, kcat, Km, and kcat/Km, for the 
utilization of dATP and 3-Eth-5-NITP by pol δ, the high-
fidelity polymerase involved in chromosomal replication 
and pol η, a specialized DNA polymerase that produces drug 
resistance by replicating damaged DNA [16, 17]. Michaelis-
Menten plots for the utilization of dATP by each polymerase 
are provided as Supplementary Figure 1, and the kinetic 
parameters derived from these plots are summarized in 
Table 1. In this analysis, the most important parameter is the 
kcat/Km value as this reflects the overall catalytic efficiency 
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of the polymerase to utilize a nucleotide substrate under 
physiological conditions. These data indicate that pol δ 
inserts dATP opposite an abasic site very poorly as the low 
kcat/Km value of 5.5 M
-1sec-1 is caused by a high Km value for 
dATP (560 ± 180 μM) coupled with a low kcat value (0.0031 
± 0.0004 sec-1). In contrast, pol η is 500-fold more efficient 
at incorporating dATP opposite the lesion. The high kcat/
Km value of 2,600 M
-1sec-1 is caused by a 12-fold lower Km 
value for dATP coupled with a ~40-fold faster kcat value. The 
observed differences in catalytic efficiencies suggest that pol 
η is more efficient than pol δ at incorporating dATP opposite 
abasic sites and thus likely contributes more to the error-
prone replication of this lesion under cellular conditions. 
Similar experiments were performed using 3-Eth-
5-NITP as the substrate (Supplementary Figure 2) and the 
resulting kinetic parameters are provided in Table 1. In the 
case of pol δ, the kcat/Km value of 6,400 M-1sec-1 for 3-Eth-
5-NITP is ~1,200-fold higher than dATP while the catalytic 
efficiency of ~68,000 M-1sec-1 measured with pol η is ~30-
fold higher than dATP. Thus, both high- and low-fidelity DNA 
polymerases utilize 3-Eth-5-NITP more efficiently than dATP. 
However, the higher efficiency observed with pol η suggests 
that specialized polymerases are primarily responsible for 
utilizing 3-Eth-5-NITP during TLS. Note that exonuclease 
proofreading activity with this particular nucleotide is 
extraordinarily low. Thus, the kinetic parameters measured 
here are not complicated by idle turnover activity and represent 
an accurate measurement of nucleotide incorporation. 
We next examined the ability of both high-fidelity 
and specialized DNA polymerases to extend beyond 
Table 1: Kinetic parameters for the incorporation of dATP and 3-Eth-5-NITP opposite an abasic 
site catalyzed by human pol δ and pol η
Nucleotide Polymerase Km (µM) kcat (sec-1) kcat/Km (M-1sec-1)
dATP pol δ 560 ± 180 0.0031 ± 0.0004 5.5 ± 1.2
dATP pol η 46 ± 11 0.12 ± 0.01 2,610 ± 550
3-Eth-5-NITP pol δ 2.0 ± 0.4 0.013 ± 0.001 6,400 ± 900
3-Eth-5-NITP pol η 3.8 ± 1.2 0.26 ± 0.06 68,420 ± 2,500
Figure 1: (A) Generalized model for translesion DNA synthesis. In this model, a DNA polymerase misinserts a nucleotide opposite a DNA 
lesion and then extends beyond it. The biological consequences of translesion DNA synthesis include the onset of drug resistance and an 
increase in mutagenesis. (B) Comparison of the chemical structures of dATP and 3-Eth-5-NITP.
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Figure 2: (A) Strategy for generating abasic sites under cellular conditions by using uracil DNA glycosylase to excise uracil from DNA 
in cells treated with UdR. (B) Exposure to uracil 2-deoxyribose increases the number of abasic sites in MOLT4 cells. MOLT4 cells were 
used at an initial density of 200,000 cells/mL and treated with 5 µM uracil 2-deoxyribose (UdR) or DMSO (vehicle control). After 72 
hours post-treatment, genomic DNA was isolated, quantified, and diluted in TE buffer to a final concentration of 100 μg/μl. The number of 
abasic sites in DNA was quantified using the aldehyde reactive probe (ARP) assay. All assays were performed in triplicate, and the means 
were calculated. Data were calculated on the basis of a linear calibration curve with ARP-DNA standard solution and expressed as number 
of apurinic sites per 100,000 nucleotides. (C) Combining 3-Eth-5-NIdR with UdR generates a synergistic cytotoxic effect compared to 
treatment with either UdR or 3-Eth-5-NIdR alone. In all cases, the initial density of MOLT4 leukemia cells was maintained at 200,000 
cells/mL prior to treatment. Cells were treated with 0.1% DMSO (vehicle), 5 µM UdR, 10 µg/mL 3-Eth-5-NIdR, and 5 µM UdR with 
10 µg/mL 3-Eth-5-NIdR for 72 hours. At this time interval, cell viability was assessed using trypan blue staining to count the number 
of viable versus non-viable cells using a hemocytometer. Cell viability was also assessed with a Muse Cell Count (EMD Millipore). 
Both assays yield results that are identical within experimental error to each other. (D) MOLT4 cells treated with DMSO or 5 µM UdR 
have low levels (< 0.5%) of AlexaFluor488 labeled DNA while cells treated with 10 µg/mL 3-Eth-5-NIdR have slightly higher levels of 
AlexaFluor488 labeled DNA (1.1%). Co-treatment with 10 µg/mL Eth-5-NIdR and 5 µM UdR results in a 6-fold increase in AlexaFluor488 
labeled DNA (6.4%). Treatment with 10 µM EdU generates considerably higher levels “clicked” genomic DNA (35.2%). 
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dAMP or 3-Eth-5-NIMP paired opposite an abasic site. 
Both mispairs were formed in situ by adding a fixed 
concentration of nucleotide substrate was added to a 
solution containing DNA substrate pre-incubated with 
DNA polymerase. After 4 half-lives, an aliquot of dTTP 
and dGTP (500 µM final concentration) was added to 
initiate the elongation reaction. Supplementary Figure 
3 provides gel electrophoresis data demonstrating that 
high-fidelity DNA polymerases such as pol δ and the 
bacteriophage T4 DNA polymerase efficiently insert 
3-Eth-5-NITP opposite an abasic site but are unable to 
elongate beyond the artificial nucleotide when supplied 
with natural dNTPs. These results validate the chain 
termination capabilities of this artificial nucleotide. 
Results obtained using pol η (provided as 
Supplementary Figure 4) are more complicated as the 
specialized DNA polymerase shows a unique ability to 
elongate one nucleotide beyond 3-Eth-5-NIMP when 
paired opposite an abasic site. Although pol η can elongate 
one base beyond the lesion, it is unable to continue primer 
elongation when supplied with high concentrations 
(> 500 µM) of natural dNTPs. Similar behavior is 
observed when pol η is supplied with dATP. In this 
case, the specialized DNA polymerase incorporates the 
artificial nucleotide opposite the lesion and also extends 
one nucleotide beyond the abasic site. However, pol η 
possesses significantly higher activity toward elongating 
beyond dAMP when supplied with natural dNTPs. This 
activity contrast data obtained with 3-Eth-NIMP which 
hinders extension beyond the DNA lesion. These results 
validate that the synthetic analog is a chain terminator of 
TLS whereas lesion by-pass can more easily occur with 
natural nucleotides. Collectively, these data validate that 
the artificial nucleotide analog likely induces cell death by 
inhibiting the by-pass of abasic sites catalyzed by either 
high-fidelity or specialized DNA polymerases. 
Measuring translesion DNA synthesis activity in 
response to chemotherapeutic agents
We next assessed the ability of 3-Eth-5-NIdR 
to potentiate the cell killing effects of TMZ, an anti-
cancer agent that generates abasic sites via alkylation 
of the N7-position of guanine [18]. Cell viability 
was directly compared in cells treated with DMSO, 
100 µM TMZ, 10 µg/mL 3-Eth-5-NIdR, and 100 µM TMZ 
combined with 10 µg/mL 3-Eth-5-NIdR. Figure 3A shows 
that treatment with either TMZ or 3-Eth-5-NIdR alone 
for three days produces weak cytostatic and cytotoxic 
effects. However, more significant effects are observed 
when TMZ is combined with a sub-lethal dose of 3-Eth-
5-NIdR as the number of viable cells decreases with a 
concomitant increase in the number of non-viable cells. 
The data provided in Figure 3B normalizes the percentage 
of non-viable cells as a function of drug exposure against 
treatment with DMSO to more easily visualize the 
synergistic effects caused by combining 3-Eth-5-NIdR 
with TMZ. As illustrated, combining 3-Eth-5-NIdR with 
TMZ produces a synergistic increase in cell death (27.5%) 
compared to the additive effects of 11.9% from cells 
treated individually with 100 µM TMZ (7.5%) or 10 µg/
mL 3-Eth-5-NIdR (4.4%).
To verify that this synergistic effect reflects the 
inhibition of TLS activity, we quantified the number 
of abasic sites produced by TMZ treatment using the 
aldehyde reactive probe (ARP) assay [14]. As illustrated in 
Figure 3C, MOLT4 cells treated with 100 µM TMZ have 
a 15% increase in the number of abasic sites compared 
to DMSO treatment. The number of abasic sites formed 
with 3-Eth-5-NIdR with treatment is identical, within 
experimental error, to the number of abasic sites produced 
using DMSO. For convenience, this data point has been 
omitted from Figure 3C. More importantly, however, 
we observe that combining 3-Eth-5-NIdR with TMZ 
produces a 35% increase in the number of abasic sites. 
This increase could result from two interrelated effects. 
First, incorporation of 3-Eth-5-NITP opposite an abasic 
site inhibits the ability of a DNA polymerase to extend 
beyond the lesion. Secondly, the incorporation of 3-Eth-
5-NITP may hinder the efficient repair of abasic sites 
formed by TMZ treatment. Note that this inhibition does 
not immediately cause cell death as cells likely attempt 
to repair stalled replication forks before undergoing 
apoptosis. Regardless, the combined effects of the 
inhibition of DNA repair and TLS activity is consistent 
with the synergistic cell-killing effects caused by 
combining 3-Eth-5-NIdR with TMZ. 
We also tested the ability of 3-Eth-5-NIdR to 
potentiate the cell killing effects of other anti-cancer drugs 
such as cisplatin, chlorambucil, carmustine, doxorubicin, 
and hydroxyurea. These agents were chosen as they 
produce DNA lesions that are structurally distinct from 
abasic sites [19–23]. Data provided in Supplementary 
Table 1 shows that co-treatment with 10 µg/mL 3-Eth-
5-NIdR does not increase the cell killing effects of 
anti-cancer agents that form DNA crosslinks (cisplatin, 
chlorambucil, and carmustine) or single-strand DNA 
(hydroxyurea). However, treatment with a sub-lethal 
concentration of 3-Eth-5-NIdR increases the cytotoxic 
effects of doxorubicin by 2-fold, and this could reflect 
the ability of 3-Eth-5-NITP to inhibit the ability of TdT to 
replicate DSBs formed by doxorubicin [15]. Collectively, 
these data coupled with the inability of 3-Eth-5-NIdR to 
potentiate the cytotoxic effects of crosslinked or alkylated 
DNA lesions indicate that the artificial nucleoside 
selectively inhibits TLS activity against non-instructional 
DNA lesions. i.e., abasic sites and DSBs. 
Inhibiting TLS activity increases apoptosis
The cellular mechanisms accounting for the 
synergistic cell killing effects caused by combining 3-Eth-
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5-NIdR with TMZ were interrogated using PI uptake and 
annexin V staining to distinguish live cells from those 
undergoing early and late stage apoptosis or necrosis. 
Representative data provided in Figure 3D show that 
MOLT4 cells co-treated with 3-Eth-5-NIdR and TMZ 
have significantly higher levels of early and late stage 
apoptosis (15.9% and 22.9%, respectively) compared to 
cells treated with TMZ (8.5% and 10.1%, respectively) 
or 3-Eth-5-NIdR (6.9% and 7.3%, respectively). Values 
provided in Table 2 represent an average of three 
independent determinations and are normalized for the 
effects of DMSO used as the co-solvent. As indicated, 
the net apoptotic effect (Δ = 28.7%) for combining 3-Eth-
5-NIdR with TMZ is 1.6-fold greater than the additive 
effects of TMZ or 3-Eth-5-NIdR treatment (Δ = 18.2%). 
The effect of this drug combination on cell cycle 
progression was next examined using PI staining to 
measure cellular DNA content. Representative histograms 
are provided in Figure 3E and a summary of three 
independent determinations are provided in Table 3. 
A baseline in cell-cycle progression was established by 
first examining cells treated with DMSO. The histogram 
displays a pattern consistent with an asynchronous cell 
population as the majority of cells exist at G0/G1 (40.0 ± 
3.2%) with smaller populations at S-phase (27.1 ± 2.5%), 
G2/M (25.0 ± 3.1%), and sub-G1 (7.9 ± 1.4%). Treatment 
with 10 µg/mL 3-Eth-5-NIdR over a three day period 
produces a similar profile (G0/G1 = 40.8 ± 3.9%, S-phase 
= 23.1 ± 3.2%, G2/M =21.5 ± 2.1%, and sub-G1= 14.6 
± 1.9%). Treatment with 100 µM TMZ also generates a 
negligible effect on the population of cells at G0/G1 (41.0 
± 4.1%). However, treatment with the DNA damaging 
agent produces small reductions in cell populations 
corresponding to S-phase (19.8 ± 1.5%) and G2/M (21.4 
± 2.4%) that occur concomitant with an increase in sub-G1 
cells (17.8 ± 2.5%). This increase is consistent with the 
induction of apoptosis caused by DNA damage after TMZ 
treatment. More importantly, combining 3-Eth-5-NIdR 
with TMZ produces higher levels in sub-G1 DNA (30.9 
± 2.9%). This effect appears cell cycle independent as it 
occurs concomitant with decreases in cell populations at 
every stage of the cell cycle (G0/G1 = 34.8 ± 2.5%, S-phase 
= 18.9 ± 1.9%, and G2M = 15.4 ± 1.5%). The synergistic 
increase in sub-G1 DNA again suggests that inhibiting 
lesion by-pass and/or the timely repair of lesions produced 
by TMZ increases apoptosis. 
Using “Click” chemistry to visualize translesion 
DNA synthesis
To verify that 3-Eth-5-NIdR inhibits TLS activity, 
high-field microscopy techniques were used to visualize 
the nucleoside in cellular DNA using “click” chemistry 
to covalently attach fluorogenic probes to the nucleotide 
incorporated into DNA. Microscopy images provided in 
Figure 4A show that MOLT4 cells treated with DMSO 
show insignificant levels of green fluorescence. This 
negative result is expected since this compound does 
not contain an alkyne moiety that can react with the 
azide-containing fluorophore. Cells treated with 10 µg/
mL 3-Eth-5-NIdR consistently display slightly elevated 
levels of green fluorescence. The merged image of green 
fluorescence with DAPI staining shows nuclear co-
localization of the AlexaFluor488 label, indicating that 
3-Eth-5-NIdR is incorporated into genomic DNA even in 
the absence of exogenous DNA damage. However, cells 
co-treated with 100 µM TMZ and 10 µg/mL 3-Eth-5-NIdR 
show significantly higher levels of green fluorescence 
which again co-localizes in the nucleus (panel D). 
Confocal microscopy images provided as Supplementary 
Figure 5 validate that the green fluorescence emanating 
from the “clicked” nucleoside co-localizes within the 
nucleus. The increased incorporation of 3-Eth-5-NITP into 
genomic DNA coincides with a higher number of abasic 
sites produced by TMZ treatment and this provides direct 
visual evidence for the replication of these DNA lesions 
inside cells. 
We next compared the extent of 3-Eth-5-NITP 
incorporation during TLS to cells treated with variable 
concentrations of EdU (0.05 to 5 µM). Images provided 
in Figure 4B show that the fluorescence signal caused by 
EdU incorporation increases as the concentration of EdU 
is raised from 0.05 to 1 µM. Above a concentration of 
1 µM, the level of fluorescence appears to plateau, and 
Table 2: Summary of dual parameter flow cytometry measuring apoptosis in MOLT4 cells
Condition Viable Early Apoptotic Late Apoptotic Necrotic Total Apoptotic
DMSO 90.0 ± 2.3% 4.4 ± 0.8% 4.8 ± 0.5% 0.8 ± 0.1% 9.2 ± 0.6%(0%)
100 µM TMZ 78.5 ± 1.8% 11.0 ± 1.1% 10.3 ± 0.9% 0.2 ± 0.1%
21.3 ± 1.0%
(12.1%)
10 µg/mL 
3-Eth-5-NIdR
84.3 ± 2.1% 7.7 ± 1.0% 7.6 ± 0.5% 0.4 ± 0.1%
15.3 ± 0.7%
(6.1%)
Combination 61.5 ± 1.5% 15.5 ± 1.1% 22.4 ± 0.9% 0.6 ± 0.1%
37.9 ± 1.0%
(28.7%)
Values represent an average of three (3) independent determinations performed on different days. Values in parenthesis 
represent the difference in percent apoptosis of treatment compared to treatment with DMSO (vehicle control). 
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Figure 3: (A) Combining sub-lethal doses of 3-Eth-5-NIdR with TMZ produces greater cytostatic and cytotoxic effects compared to 
treatment with 100 µM TMZ or 10 µg/mL 3-Eth-5-NIdR alone. In all cases, the initial density of MOLT4 leukemia cells was maintained 
at 200,000 cells/mL prior to treatment. Cells were treated with 0.1% DMSO (vehicle), 100 µM TMZ, 10 µg/mL 3-Eth-5-NIdR, and 
100 µM TMZ with 10 µg/mL 3-Eth-5-NIdR for 72 hours. At this time interval, cell viability was assessed using trypan blue staining and 
flow cytometry as described in the text. Open (white) bars represent viable cells while gray bars represent non-viable cells. ** represents a 
p value of > 0.01 while *** represents a p value of > 0.001. (B) Secondary plot based on primary data provided in Figure 2A comparing 
the % non-viable cells as a function of various drug treatments. In all cases, the values representing percent apoptosis caused by various 
treatment are normalized for cell death measured in the presence of DMSO (vehicle control). This analysis demonstrates that combining 
3-Eth-5-NIdR with TMZ produces a 27.5% increase in the percentage of non-viable cells compared to increases of 7.5% and 4.4% with 
100 µM TMZ or 10 µg/mL 3-Eth-5-NIdR, respectively. Thus, the combination of 3-Eth-5-NIdR with TMZ generates a synergistic increase 
in apoptosis as it is greater than the predicted additive effects. *** represents a p value of > 0.001 (C) Combining 3-Eth-5-NIdR with TMZ 
increases the number of abasic sites. MOLT4 cells were used at an initial density of 200,000 cells/mL and treated with DMSO (vehicle 
control), 100 µM TMZ, or 100 µM TMZ with 10 µg/mL 3-Eth-5-NIdR. After 72 hours post-treatment, genomic DNA was isolated, 
quantified, and diluted in TE buffer to a final concentration of 100 μg/μl. The number of abasic sites in DNA was quantified using the 
aldehyde reactive probe (ARP) assay. All assays were performed in triplicate, and the means were calculated. Data were calculated on the 
basis of a linear calibration curve with ARP-DNA standard solution and expressed as number of apurinic sites per 100,000 nucleotides. 
(D) MOLT4 cells treated with 3-Eth-5-NIdR and TMZ have significantly higher levels of early and late stage apoptosis compared to cells 
treated with TMZ or 3-Eth-5-NIdR alone. Cells (100,000 – 200,000 cells/mL) were treated with 0.1% DMSO (vehicle), 100 µM TMZ, 
10 µg/mL 3-Eth-5-NIdR, and 100 µM TMZ with 10 µg/mL 3-Eth-5-NIdR for 48 hours. Cells were harvested by centrifugation, washed 
in PBS, and re-suspended in 100 µL of binding buffer containing 5 µM of Annexin V-Alexa Fluor 488 conjugate. Cells were treated with 
1 µg/ mL PI and incubated at room temperature for 15 min followed by flow cytometry analysis. Cells were analyzed using either Muse Cell 
analyzer or Beckman Coulter EPICS-XL with EXPO 32 Data Acquisition software. 15,000-gated events were observed for each sample. 
(E) Analysis of cell-cycle progression in MOLT4 treated with TMZ in the absence and presence of 3-Eth-5-NIdR. Cells (100,000–200,000 
cells/mL) were treated with 0.1% DMSO (vehicle), 100 µM TMZ, 10 µg/mL 3-Eth-5-NIdR, and 100 µM TMZ with 10 µg/mL 3-Eth-5-
NIdR for 48 hours. Cells were harvested by centrifugation, washed in PBS, and treated with 1 µg/ mL PI. Cells were incubated at room 
temperature for 15 min followed by flow cytometry analysis. Cells were analyzed using either Muse Cell analyzer or Beckman Coulter 
EPICS-XL with EXPO 32 Data Acquisition software. 15,000-gated events were observed for each sample. 
Oncotarget40811www.impactjournals.com/oncotarget
this may reflect saturation kinetics in the uptake of EdU 
and/or its metabolism to the corresponding nucleoside 
triphosphate [24, 25]. Regardless, microscopy images 
provided in Figure 4A show that cells treated with 3-Eth-5-
NIdR and TMZ display fluorescence levels that are similar 
to cells treated with 0.5 µM EdU. This conclusion was 
verified by quantifying the amount of fluorescently labeled 
DNA isolated from cells treated with 3-Eth-5-NIdR and 
TMZ and comparing it to DNA isolated from cells treated 
with variable concentrations of EdU (0.05–5 µM). Figure 
4C provides a standard curve showing an excellent linear 
correlation (r2 = 0.98) in fluorescence signal as a function 
of increasing EdU concentrations (from 0.01 to 1 µM). 
This standard curve was used to determine that DNA 
isolated from cells treated with TMZ and 3-Eth-5-NIdR 
displays a level of fluorescence that is comparable to DNA 
isolated from cells treated with 0.5 µM EdU. Collectively, 
the results from the microscopy analyses coupled with 
quantitation of purified DNA from cells verify that 3-Eth-
5-NIdR is incorporated opposite DNA lesions generated 
by TMZ treatment. 
DISCUSSION 
TLS is an important biological pathway that provides 
cells with an effective way to survive genomic stress 
caused by unrepaired DNA lesions. Unfortunately, this 
process can also produce detrimental effects at the cellular 
and organismal levels. Indeed, unregulated TLS activity 
is involved in the initiation and progression of diseases 
such as cancer as well as in generating drug resistance 
to therapeutic agents used to treat this disease. Despite 
the importance of TLS, a complete understanding of this 
process has been hindered by the lack of biochemical 
tools that can directly measure the replication of damaged 
DNA inside cells. This report addresses this deficiency 
by using an artificial nucleoside to quantify TLS activity 
in cells treated with DNA damaging agents. Our results 
provide key insights into three fundamentally important 
areas. These include defining the roles of high-fidelity 
and low fidelity DNA polymerases toward replicating 
damaged DNA, the development of a diagnostic assay 
to predict how TLS activity affects therapeutic responses 
to anti-cancer agents, and a new therapeutic strategy to 
improve the efficacy of DNA damaging agents used in 
chemotherapy. Each area is discussed in more detail 
below. 
Currently, there are two accepted models for how 
DNA polymerase activity is coordinated during TLS 
[26, 27]. In the first model, a high-fidelity DNA 
polymerase such as pol δ encounters an unrepaired DNA 
lesion during chromosomal replication. After incorporating 
a nucleotide opposite the lesion, the polymerase is unable 
to extend beyond it. Subsequent stalling of the replication 
fork the recruits a specialized DNA polymerase such as 
pol κ or pol ζ to extend beyond the lesion. Once lesion 
by-pass occurs, pol δ displaces the specialized polymerase 
and resumes DNA synthesis downstream of the damaged 
DNA. The second model varies slightly as the intrinsic 
high-fidelity of pol δ prevents it from incorporating a 
nucleotide opposite the lesion. Instead, a specialized DNA 
polymerase such as pol η is recruited to incorporate a 
dNTP opposite the lesion. After pol η by-passes the lesion, 
pol δ replaces the specialized polymerase and continues 
chromosomal replication. In general, the in vitro kinetic 
data provided here are consistent with this second model as 
pol δ displays low TLS activity as evident in a remarkably 
low catalytic efficiency for incorporating dATP opposite 
an abasic site. In contrast, pol η is far more proficient at 
incorporating dATP and 3-Eth-5-NITP opposite the non-
instructional DNA lesion. More importantly, pol η utilizes 
3-Eth-5-NITP ~10-fold more efficiently than dATP. This 
higher efficiency coupled with the chain-termination 
capabilities of the artificial nucleotide suggests that 3-Eth-
5-NITP preferentially inhibits TLS catalyzed by pol η. The 
inhibitory effects against this specialized DNA polymerase 
explains how 3-Eth-5-NIdR increases the cytotoxic effects 
of compounds such as UdR and TMZ that create non-
instructional DNA lesions such as abasic sites. 
Expanding on these results, we applied “click” 
chemistry to selectively and covalently attach fluorogenic 
probes to 3-Eth-5-NIdR to visualize the cellular activity of 
Table 3: Summary of the effects of drug treatment on cell cycle progression in MOLT4 cells
Condition G0/G1 S-Phase G2/M SubG1
DMSO 40.0 ± 3.2% 27.1 ± 2.5% 25.0 ± 3.1% 7.9 ± 1.4%(0%)
100 µM TMZ 41.0 ± 4.1% 19.8 ± 1.5% 21.4 ± 2.4%
17.8 ± 2.5%
(9.9%)
10 µg/mL 
3-Eth-5-NIdR
40.8 ± 3.9% 23.1 ± 3.2% 21.5 ± 2.1%
14.6 ± 1.9%
(6.7%)
Combination 34.8 ± 2.5% 18.9 ± 1.9% 15.4 ± 1.5%
30.9 ± 2.9%
(23.0%)
Values represent an average of three (3) independent determinations performed on different days. Values in parentheses 
represent the difference in percent sub-G1 DNA measured with various treatments compared to treatment with DMSO (vehicle 
control). 
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pol η during TLS. This has important clinical applications, 
particularly with respect to developing diagnostic tests 
to determine patient responses to anti-cancer agents 
that damage DNA. Accurately measuring the effects of 
chemotherapeutic agents has obvious implications for 
facilitating successful patient responses to drug treatment. 
This is especially relevant with therapeutic agents such as 
cisplatin, doxorubicin, and TMZ which are widely used 
to treat breast, pancreatic, and brain cancer. To date, most 
efforts in the area of personalized medicine have focused 
on using genomic and/or proteomic profiling techniques to 
identify prognostic biomarkers for therapeutic intervention. 
Several groups have shown that higher POLH expression 
correlates with poor patient outcomes, particularly with 
respect to treatment with DNA damaging agents [28–30]. 
Unfortunately, similar genetic approaches have failed 
to produce clear correlations in patient responses to 
chemotherapy with other specialized DNA polymerases 
such as pol k and pol z [31–33]. These discrepancies likely 
reflect the complexities associated with the large number 
and diversity of human DNA polymerases that can cause 
drug resistance by replicating damaged DNA. We propose 
that 3-Eth-5-NITP can overcome these complications since 
this artificial nucleotide behaves as a universal and highly 
selective substrate for chromosomal and specialized DNA 
polymerase that replicate abasic sites. The unique ability 
of 3-Eth-5-NIdR to directly measure TLS activity against 
this lesion can be used in activity-based assays to quantify 
the collective activity of all cellular DNA polymerases that 
perform TLS. This activity based assay would provide 
more physiologically relevant data compared to genomic 
and proteomic techniques which simply infer enzyme 
activity by measuring mRNA or protein levels. 
Finally, the data provided here clearly show the 
potential therapeutic utility for inhibiting TLS activity 
as a way to increase the cell killing effects of anti-cancer 
agents that damage DNA. Our data demonstrate that low 
concentrations of 3-Eth-5-NIdR significantly increase 
the cytotoxicity of TMZ by inhibiting TLS activity. This 
inhibition could produce several beneficial effects in patients 
receiving chemotherapy. For instance, sensitizing cancer 
cells to the effects of a DNA damaging agent provides a 
strategy to administer lower drug doses which would reduce 
the risk of potential side effects. Again, this is particularly 
important with drugs such as cisplatin and cyclophosphamide 
that produce severe and debilitating side effects. Indeed, the 
ability of the these agents to non-selective kill of healthy yet 
rapidly proliferating cells such as B- and T-cells accounts for 
side effects such as leukopenia and thrombocytopenia that 
can compromise a patient’s response to chemotherapy [34]. 
Finally, targeting TLS activity also provides a rationale way 
to combat drug resistance caused by the up-regulation of pro-
mutagenic DNA synthesis.
MATERIALS AND METHODS
Cells and cell culture
MOLT4 cells were cultured in a humidified 
atmosphere of 5% CO
2 
at 37° C. Cells were maintained in 
ATCC-formulated RPMI-1640 media supplemented with 
10% fetal bovine serum (FBS), 5% L-glutamine, and 0.5% 
penicillin/streptomycin (Invitrogen, NY). 
Reagents
Phosphate-buffered saline (PBS), antibiotic and 
antifungal agents, amphotericin, propidium iodide, 
PrestoBlue, DAPI, Alexa Fluor 488, and apoptosis 
assay kit containing Alexa Fluor 488-labeled Annexin V 
were from Invitrogen. 3-Eth-5-NIdR and 3-Eth-5-NITP 
were synthesized and purified as previously described 
[13, 15]. DNA including that containing an abasic site 
were obtained from Operon and purified as described 
[13, 15]. Recombinant human polymerase delta (pol δ) and 
human polymerase eta (pol η) were purified as previously 
described [35, 36]. Each polymerase was judged to 
be > 97% pure as assessed by sodium dodecylsulfate-
polyacrylamide denaturing gel electrophoresis.
Cell viability assays
3-Eth-5-NIdR was added to wells in a dose-dependent 
manner (1−100 µg/mL) and treated for variable time periods 
(24−72 hr). In all cases, the final concentration of the co-
solvent, DMSO, was maintained at 0.1%. Cell viability was 
assessed using trypan blue staining to count the number of 
viable versus non-viable cells using a hemocytometer. Cell 
viability was also assessed with a Muse Cell Count (EMD 
Millipore). IC50 values for the artificial nucleoside and anti-
cancer agents were obtained using a non-linear regression 
curve fit of the data to Equation 1. 
y = 100% / (1 + (IC50/[Compound])) (1)
LD50 values for the artificial nucleoside were 
calculated using identical approaches. 
Figure 4: (A) Microscopy analyses monitoring the incorporation of 3-Eth-5-NIdR opposite abasic sites generated by TMZ treatment. 
Cells were co-treated with 100 µM TMZ, 10 µg/mL 3-Eth-5-NIdR, and a combination of 100 µM TMZ and 10 µg/mL 3-Eth-5-NIdR for 
three days. Cells treated with a combination of 100 µM TMZ and 10 µg/mL 3-Eth-5-NIdR display significantly higher levels of green 
fluorescence that co-localizes in the nucleus compared to cells treated with 100 µM TMZ or 10 µg/mL 3-Eth-5-NIdR alone. (B) Microscopy 
images of MOLT4 cells treated with increasing concentrations of EdU (0.05 to 5 µM). The fluorescence signal reflecting EdU incorporation 
increases as the concentration of EdU is raised from 0.05 to 1 µM. See text for experimental details. (C) The standard curve for the 
fluorescence of DNA “clicked” with EdU versus the concentration of EdU is linear (r2 = 0.98). DNA isolated from MOLT4 cells treated 
with 3-Eth-5-NIdR and TMZ (■) shows a level of fluorescence comparable to 0.5 µM EdU. See text for experimental details regarding the 
generation of the standard curve used to determine the amount of 3-Eth-5-NITP incorporated into genomic DNA. 
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Apoptosis measurements
Cells (100,000 – 200,000 cells/mL) were treated 
with 0.1% DMSO (vehicle), 5 µM UdR, 10 µg/mL 3-Eth-
5-NIdR, and 5 µM UdR with 10 µg/mL 3-Eth-5-NIdR 
for 48 hours. Cells were harvested by centrifugation, 
washed in PBS, and re-suspended in 100 µL of binding 
buffer containing 5 µM of Annexin V-Alexa Fluor 488 
conjugate. Cells were treated with 1 µg/ mL PI and 
incubated at room temperature for 15 min followed by 
flow cytometry analysis. Cells were analyzed using either 
Muse Cell analyzer or Beckman Coulter EPICS-XL with 
EXPO 32 Data Acquisition software. 15,000-gated events 
were observed for each sample. 
“Click” reactions were performed using cells 
harvested after 2 days of treatment with DMSO, EdU (0–5 
μM), TMZ (100 µM), 3-Eth-5-NIdR (10 μg/mL), or TMZ 
(100 µM) with 3-Eth-5-NIdR (10 μg/mL). All cells were 
fixed with cold methanol overnight. Cells were treated 
with 0.3 mL of saponin-based permeabilization and wash 
buffer for 45 min at 37 °C. Click reactions were initiated 
with click-iT reaction cocktail followed by incubation at 37 
°C for 90 min. Cells were washed twice with wash buffer. 
Cell pellets were dislodged using 0.5 mL solution of 10 μg/
mL PI and RNAase A in saponin-based permeabilization 
buffer. Cells were incubated for 15 min with 1 µg/mL 
DAPI prior to analysis. Images were obtained using an 
EVOS
fl
 Advanced microscope (40X magnification).
Kinetic parameters for nucleotide incorporation
Kinetic studies using polymerase delta and polymerase 
eta were performed using an assay buffer consisting of 
50 mM TrisOAc, 1 mg/mL bovine serum albumin, 10 mM 
DTT, and 5 mM MgCl
2
 at pH 7.5. All assays were performed 
at 37°C. kcat, Km, and kcat/Km values for nucleotides were 
measured as described (37). Data for the dependency of 
rate as a function of nucleotide concentration were fit to the 
Michaelis–Menten equation (Equation 3):
ν = Vmax * [dXTP] / (Km + [dXTP]) (3) 
where ν is the rate of product formation analysis, the 
most important parameter (nM/s), Vmax is the maximal rate 
of polymerization, Km is the Michaelis constant for dXTP, 
and [dXTP] is the concentration of nucleotide substrate. 
The turnover number, kcat, is Vmax divided by the final 
concentration of polymerase used in each assay.  
Chain-termination experiments
 Assays were performed using pseudo-first order 
reaction conditions in which a limiting concentration of 
DNA polymerase (25 nM) was pre-incubated with 500 
nM DNA containing an abasic site in assay buffer and 
then mixed with a fixed concentration of dATP (500 µM) 
or 3-Eth-5-NITP (5 µM) to initiate insertion opposite 
the lesion. After 4 half-lives, an aliquot of dTTP and 
dGTP (500 µM final concentration) was added to initiate 
the elongation reaction. Aliquots of the reactions were 
quenched with 200 mM EDTA at variable times (0-30 
minutes) and analyzed by denaturing gel electrophoresis 
to assess elongation beyond dATP or 3-Eth5-NITP. 
Quantifying abasic site formation
DNA was isolated using the genomic DNA mini 
kit as described by the manufacturer (IBI Scientific). The 
concentration and purity of isolated DNA was measured 
using agarose gel electrophoresis and spectrophotometric 
analyses (Spectramax M4, Molecular Devices). Genomic 
DNA was diluted in TE buffer to a final concentration of 
100 μg/μl. Measurements were performed with the use of 
a commercially available kit for abasic sites site counting 
(DNA Damage Quantification Kit, Dojindo Molecular 
Technologies). All assays using the aldehyde reactive 
probe (ARP) were performed in triplicate, and the means 
were calculated. Data were calculated on the basis of a 
linear calibration curve with ARP-DNA standard solution 
and expressed as number of apurinic sites per 100,000 
nucleotides.
Statistical analyses
All data showing error bars are presented as mean 
± s.e.m. The significance of difference in the mean value 
was determined using a two-tailed Student’s t-test and 
normal distribution was assumed in all cases. A one-way 
ANOVA analysis was used to compare the effects of cells 
treated with the combination of 3-Eth-5-NIdR and DNA 
damaging agent versus treatment with DMSO, 3-Eth-
5-NIdR, and DNA damaging agent alone to determine 
p-values. P-values < 0.05 were considered significant. 
All calculations were performed using KaleidaGraph 
software. All cell culture experiments were reproduced at 
least three times independently. For each experiment, the 
number of samples and replicates are provided in the text 
or figure legend. 
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